<DOC>
	<DOCNO>NCT00586820</DOCNO>
	<brief_summary>Percutaneous coronary intervention ( PCI ) acute coronary syndrome frequently fail restore myocardial perfusion despite establish epicardial vessel patency . Endothelin-1 ( ET-1 ) potent vasoconstrictor expression increase atherosclerotic coronary artery . Our hypothesis increase activity endogenous endothelin system contribute microvascular dysfunction , adjunctive therapy endothelin receptor antagonist result improve microvascular blood flow . Aims : The aim study assess patient non ST-elevation myocardial infarction , whether : 1 ) PCI cause increase coronary blood ET-1 level ; 2 ) endothelin receptor antagonist acutely improve coronary microvascular blood flow follow PCI . Non-ST segment elevation myocardial infarction ( NSTEMI ) one type heart attack . It define development heart muscle necrosis result acute interruption blood supply part heart demonstrate elevation cardiac marker Creatinine Kinase Isoenzyme Muscle/Brain Type ( CK-MB ) blood absence ST-segment elevation ECG ( electrocardiography ) . ST-segment portion ECG , elevation indicate full thickness damage heart muscle . Absence ST-segment elevation NSTEMI indicate partial thickness damage heart muscle occur . Therefore , NSTEMI less severe type heart attack compare STEMI ( ST-segment elevation myocardial infarction ) full thickness damage heart muscle occurs .</brief_summary>
	<brief_title>Role Endothelin Microvascular Dysfunction Following PCI NSTEMI</brief_title>
	<detailed_description>Our hypothesis endogenous endothelin system contribute microvascular dysfunction impair myocardial reperfusion follow successful PCI non ST-elevation MI , endothelin receptor antagonism improve microvascular flow . The study provide new insight humoral regulation microcirculation patient present acute coronary syndrome . General method : This section describe approach investigate specific aim . The study prospective , double blind , placebo-controlled trial ass efficacy selective endothelin type A receptor antagonist ( BQ-123 ) , adjunctive therapy PCI non ST elevation MI . The control group receive placebo rather another vasodilator order specifically elucidate role endogenous endothelin system .</detailed_description>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Myocardial Reperfusion Injury</mesh_term>
	<mesh_term>cyclo ( Trp-Asp-Pro-Val-Leu )</mesh_term>
	<criteria>Age â‰¥ 18 year Clinical diagnosis unstable angina non STelevation myocardial infarction , require clinically indicate PCI management non ST elevation acute coronary syndrome . Systemic hypotension ( systolic &lt; 90 mmHg ) Heart failure know ejection fraction &lt; 30 % Left main disease Culprit lesion saphenous vein graft 100 % occlusion culprit vessel culprit ostial right coronary stenosis Currently enrol active cardiovascular investigational study Severe endocrine , hepatic , renal disorder Pregnancy lactation Federal Medical Center inmates Inability unwillingness provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Coronary Atherosclerosis</keyword>
	<keyword>Microvascular Dysfunction</keyword>
	<keyword>Non-ST Elevation Myocardial Infarction</keyword>
</DOC>